Format

Send to

Choose Destination
See comment in PubMed Commons below
J Natl Cancer Inst. 2015 Jul 16;107(9). pii: djv169. doi: 10.1093/jnci/djv169. Print 2015 Sep.

Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk.

Author information

  • 1Imperial College, London, UK (MJG); Albert Einstein College of Medicine, Bronx, NY (TW, XX, SWS, HDS, TER, RCK, DW, GYFH); University of Vermont, Burlington, VT (MC); Brigham and Women's Hospital, Harvard Medical School, Boston, MA (JEM); Fred Hutchinson Cancer Research Center, Seattle, WA (AM); University of Texas Southwestern Medical School, Dallas, TX (PES); University of California Los Angeles, Torrence, CA (RTC); University of Iowa, Iowa City, IA (LS). m.gunter@imperial.ac.uk.
  • 2Imperial College, London, UK (MJG); Albert Einstein College of Medicine, Bronx, NY (TW, XX, SWS, HDS, TER, RCK, DW, GYFH); University of Vermont, Burlington, VT (MC); Brigham and Women's Hospital, Harvard Medical School, Boston, MA (JEM); Fred Hutchinson Cancer Research Center, Seattle, WA (AM); University of Texas Southwestern Medical School, Dallas, TX (PES); University of California Los Angeles, Torrence, CA (RTC); University of Iowa, Iowa City, IA (LS).

Abstract

BACKGROUND:

Adipokines and inflammation may provide a mechanistic link between obesity and postmenopausal breast cancer, yet epidemiologic data on their associations with breast cancer risk are limited.

METHODS:

In a case-cohort analysis nested within the Women's Health Initiative Observational Study, a prospective cohort of postmenopausal women, baseline plasma samples from 875 incident breast cancer case patients and 839 subcohort participants were tested for levels of seven adipokines, namely leptin, adiponectin, resistin, interleukin-6, tumor necrosis factor-α, hepatocyte growth factor, and plasminogen activator inhibitor-1, and for C-reactive protein (CRP), an inflammatory marker. Data were analyzed by multivariable Cox modeling that included established breast cancer risk factors and previously measured estradiol and insulin levels. All statistical tests were two-sided.

RESULTS:

The association between plasma CRP levels and breast cancer risk was dependent on hormone therapy (HT) use at baseline (P interaction = .003). In a model that controlled for multiple breast cancer risk factors including body mass index (BMI), estradiol, and insulin, CRP level was positively associated with breast cancer risk among HT nonusers (hazard ratio for high vs low CRP levels = 1.67, 95% confidence interval = 1.04 to 2.68, P trend = .029). None of the other adipokines were statistically significantly associated with breast cancer risk. Following inclusion of CRP, insulin, and estradiol in a multivariable model, the association of BMI with breast cancer was attenuated by 115%.

CONCLUSION:

These data indicate that CRP is a risk factor for postmenopausal breast cancer among HT nonusers. Inflammatory mediators, together with insulin and estrogen, may play a role in the obesity-breast cancer relation.

PMID:
26185195
PMCID:
PMC4651104
DOI:
10.1093/jnci/djv169
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center